Christopher D. T. Guiffre, J.D., M.B.A.
President & Chief Executive Officer
Chris has served as a member of our board of directors and as our President and Chief Executive Officer since March 2015. He previously served as Chief Operating Officer and as Senior Vice President and Chief Business Officer. Prior to that, Mr. Guiffre held a number of senior executive positions at various biopharmaceutical companies, including President and Chief Executive Officer of Alvos Therapeutics, Inc., Chief Business Officer at Hydra Biosciences, Inc., and a senior executive at Cubist Pharmaceuticals, Inc., most recently as Senior Vice President, General Counsel and Secretary. Mr. Guiffre has also held several positions at Renaissance Worldwide, Inc., including Vice President, General Counsel and Clerk. Prior to that, he was an Associate at Bingham, Dana & Gould LLP (now a part of Morgan, Lewis & Bockius LLP). Mr. Guiffre received a B.S. from Babson College, a J.D. from Boston College Law School, and an M.B.A. from Boston College Carroll School of Management.Back to Top
Gregg D. Beloff, J.D., M.B.A.
Chief Financial Officer
Gregg has served as Chief Financial Officer since May 2015. Mr. Beloff joined Cerulean as a member of Danforth Advisors, a consulting firm specializing in providing financial and strategic support to life sciences companies. In addition to his consulting for clients, Mr. Beloff previously served as the Chief Financial Officer of two public and three privately held companies. In these roles, he managed finance, accounting, corporate communications, human resources, information technology, facilities, legal, intellectual property, business development, and manufacturing functions. Mr. Beloff holds a J.D. from the University of Pittsburgh School of Law, an M.B.A. from Carnegie Mellon University and a B.A. in History from Middlebury College.
Scott Eliasof, Ph.D.
Senior Vice President and Chief Scientific Officer
Scott has served as our Senior Vice President and Chief Scientific Officer since October 2016 and has led our research team since 2007. He previously served as Vice President of Research. Prior to joining Cerulean, he was the director of the Chemical Biology Platform at the Broad Institute, directing a multi-disciplinary team of professional scientists and technicians in the fields of synthetic chemistry, analytical chemistry, high-throughput screening, computational science, and software engineering. This interdisciplinary organization is closely affiliated with the laboratory of Stuart Schreiber from Harvard University and is one of the largest and oldest academic screening centers in the country. Prior to joining the Broad Institute, Mr. Eliasof worked at Millennium Pharmaceuticals, where he managed scientific teams in cellular biology, molecular biology, neuroscience, and bioinformatics for a large-scale genomics-based drug discovery program. Earlier in his career, Mr. Eliasof was at Neurocrine Biosciences, where he played a key role in the exploration of glutamate transporters in the field of stroke and neurological disorders. Mr. Eliasof earned his B.S. from MIT in electrical engineering, Ph.D. from the University of California at Berkeley in neuroscience, and completed his post-doctoral fellowship at the Vollum Institute in Portland, Oregon.Back to Top
Adrian M. Senderowicz, M.D.
Senior Vice President and Chief Medical Officer
Adrian has served as our Senior Vice President and Chief Medical Officer since September 2015. Dr. Senderowicz was Chief Medical Officer and Senior Vice President, Clinical Development and Regulatory Affairs at Ignyta, Inc., a precision oncology biotechnology company, where he served from 2014 to 2015. Prior to joining Ignyta, he served as Vice President, Global Regulatory Oncology at Sanofi from 2013 to 2014, Chief Medical Officer at Tokai Pharmaceuticals from 2012 to 2013, and Senior Medical Director, Oncology Clinical Development at AstraZeneca from 2008 to 2012. Before his tenure at AstraZeneca, Dr. Senderowicz held a variety of leadership positions at the U.S. Food and Drug Administration Division of Oncology Drug Products in the Center for Drug Evaluation and Research and a variety of clinical and research positions with the National Cancer Institute/National Institutes of Health, or NCI, including Investigator and Chief, Molecular Therapeutics Unit. He currently serves as a member of the board of directors of Puma Biotechnology, Inc., a publicly traded biopharmaceutical company. He completed his internal medicine residency training at the Icahn School of Medicine at Mount Sinai, and a clinical oncology fellowship at the NCI. Dr. Senderowicz holds an M.D. from the School of Medicine at the Universidad de Buenos Aires in Argentina.Back to Top
Alejandra V. Carvajal, J.D.
Vice President, General Counsel
Alejandra has served as our Vice President and General Counsel since 2014. Prior to joining Cerulean, Ms. Carvajal worked at Millennium: The Takeda Oncology Company from 2004 to 2014, where she held a variety of positions, including most recently Associate General Counsel. Ms. Carvajal joined Millennium as a senior attorney and enjoyed over ten years of increasing responsibilities relating to all aspects of oncology drug development. Prior to joining Millennium, Ms. Carvajal was an attorney with the law firms Day, Berry & Howard and Hill & Barlow. Ms. Carvajal received a B.A. cum laude from Harvard University and a J.D. cum laude from Georgetown University Law Center.Back to Top
Vice President, Clinical Operations
Tiffany has served as Vice President, Clinical Operations since 2015. Prior to joining Cerulean, Ms. Crowell spent approximately three years in positions of increasing responsibility in clinical operations, most recently as Vice President, Clinical Operations at AVEO Pharmaceuticals, Inc. Prior to AVEO, Ms. Crowell led the clinical operations efforts at Inotek Pharmaceuticals Corporation, and managed clinical operations at Vertex Pharmaceuticals. Previously, she managed clinical trials at companies including Therion Biologics and V. I. Technologies. Ms. Crowell also held process development and operations roles at Biopure Corporation and Oravax Incorporated. She started her career as a Chemist for Wyeth Ayerst Laboratories. Ms. Crowell received a B.S. in Chemistry from Randolph-Macon Woman's College.Back to Top